

# diabetes

A JOURNAL OF  
THE AMERICAN  
DIABETES  
ASSOCIATION®


www.diabetes.org/diabetes

## ABSTRACT BOOK

69<sup>th</sup> Scientific Sessions

Friday, June 5–Tuesday, June 9, 2009

Moial Convention Center  
New Orleans, LA

 American Diabetes Association  
Care • Cure • Commitment®

**69<sup>th</sup> scientific sessions**

JUNE 5-9, 2009 • NEW ORLEANS, LA

2009 Officers and Board of Directors	1
Past Officers	4
Journal Editors	6
2009 Scientific Achievement Award Recipients	7
2009 Banting Medal for Scientific Achievement Recipient	8
2009 Outstanding Scientific Achievement Award Recipient	9
2009 Outstanding Educator in Diabetes Award Recipient	10
Previous Scientific Achievement Award Recipients	11
2009 Professional Section Interest Group Chairs	13
2009 New Research Grants Awarded	14
2009 Scientific Sessions Meeting Planning Committee	19
Scientific Sessions Abstract Reviewers	19
General Information	21
Scientific Sessions Poster Sessions and Receptions Schedule	23
Corporate Symposia	26
Young Investigator Travel Grant Award Recipients	29
Scientific Sessions Day at a Glance	32
Oral Abstract Presentations	38
Exhibitors	66
Abstracts	A1
Subject Index	AB47
Abstract Author Index	A685
Disclosure Information	A713

 American  
Diabetes  
Association®  
Care • Cure • Commitment®

DIABETES 74 Supplement C/D 1–A734 (2009)  
ISSN 0892-2757

### Significant Improvements in Glycemic Control without Weight Gain with Insulin Detemir in Clinical Reality: Experience from Macedonian Clinical Practice

CEDOMIR DIMITROVSKI, IVICA SMOKOVSKI, SNEZANA MAKREVSKA, ISKIRA MILEVA, MIRA KOSTOJCINOVSKA, *Skopje, The former Yugoslav Republic of Macedonia, Kumanovo, The former Yugoslav Republic of Macedonia, Struga, The former Yugoslav Republic of Macedonia*

Unwanted weight gain is a recognized side-effect of insulin therapy, and can act as a barrier to insulin initiation and intensification. This prospective, multi-center, 24-week observational study explored efficacy, weight change and safety for insulin detemir (IDet) use in type 1 and 2 diabetes patients under normal clinical practice conditions in Macedonia. Results presented are for 1053 patients on various regimens from 30 diabetes centers (44.7% male; mean age  $60.0 \pm 12.3$  y; type 2 diabetes 93.4%; diabetes duration  $8.7 \pm 6.4$  y; BMI  $28.1 \pm 4.9$  kg/m<sup>2</sup>) inadequately controlled on prior treatment (50.8% with OAD; 38.7% with insulin). Most patients were initiated with (76.6%) and/or completed the study (80.3%) on once-daily IDet. Baseline and 24-week total daily insulin doses (U/day) were  $25.2 \pm 10.9$  and  $29.4 \pm 9.7$ , respectively. For patients on basal-bolus therapy, total daily bolus insulin (insulin aspart) dose was reduced from  $27.0 \pm 11.9$  U at baseline to  $22.1 \pm 13.0$  U at week 24 (n=197). At 24 weeks, mean HbA1c and FPG were significantly improved compared to baseline. The proportion of patients achieving target HbA1c <7% increased from baseline (11.7% vs 38.8% at week 24). Despite an improvement in HbA1c of 1.78%, there was a trend for modest weight reduction (Table). No major hypoglycemic events were reported and no safety issues were raised during the study. Our findings support data from randomized controlled trials that show once-daily IDet can be used to bring about clinically important improvements in glycemic control without weight gain.

#### Change from baseline to endpoint following IDet use

	Baseline	24 Weeks	Change (Baseline-24 Weeks)	p-value
HbA1c (%)	$9.23 \pm 1.97$	$7.40 \pm 1.06$	$-1.78 \pm 1.81$	<0.0001
FPG (mg/dL)	$193.86 \pm 67.32$	$126.54 \pm 22.5$	$-63.90 \pm 67.32$	<0.0001
Weight (kg)	$76.38 \pm 14.0$	$75.75 \pm 12.38$	$-0.81 \pm 11.66$	0.08

